SubsidieMeestersEnabling efficient cell engineering leaving gene-expression BURden OUT for cell therapies and biopharmaceutical industry
BURnOUT is an AI-driven software designed to optimize gene sequences for efficient mammalian cell engineering, aiming to reduce costs and enhance therapies for cancer and biopharmaceuticals.
Projectdetails
Introduction
Mammalian cell engineering has emerged as a new ground-breaking modality for the development of cell-based therapies to treat several hard-to-cure diseases, including cancer (T cell-based immunotherapies). It is also used to produce molecules with diagnostic and therapeutic applications such as monoclonal antibodies (mAbs), which are now a dominant product class in the biopharmaceutical industry.
Challenges in Cell Engineering
However, the pipeline for efficient design-test-commercialization of the product is long and expensive. This is even more pronounced when cells must be engineered with two or more transgenes, which is an increasing need in T cell-based therapies or drug production. For example, cells may be engineered to produce enzymes and co-enzymes, or antibody cocktails.
At the core of the problem is the competition for a finite number of intracellular resources, both transcriptional and translational. This competition causes an unbalanced expression of products, thus hampering the therapeutic effect.
BURnOUT: A Solution
BURnOUT is an Artificial Intelligence and Machine Learning-based software that will provide, in an automated manner, paired gene sequence optimization to accelerate the process of mammalian cell engineering.
Validation Settings
BURnOUT will be validated in two different settings:
- Biopharmaceutics: Engineered CHO cell lines for antibody production.
- Cell therapy: Engineering T cells for multiple CARs expression.
Impact and Goals
The successful validation of the technology will be of trans- and multi-disciplinary interest. It aims to target a wide variety of markets in Life Science, from AI to synthetic biology for cell and gene therapies, and global cell technologies for the drug industry.
We envision that BURnOUT will respond to current strategic societal needs and challenges, such as:
- Reduced costs of biopharmaceutics.
- More effective treatment for cancer.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-9-2024 |
| Einddatum | 28-2-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIApenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Engineering B cells to fight cancerThis project aims to develop a novel cancer immunotherapy using engineered B cells to enhance anti-tumor responses through targeted gene integration and localized immune activation. | ERC Consolid... | € 1.996.250 | 2022 | Details |
Polyclonal anti-tumor immunity by engineered human T cellsThis project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes. | ERC Starting... | € 1.812.500 | 2022 | Details |
Learning and modeling the molecular response of single cells to drug perturbationsDeepCell aims to model cellular responses to drug perturbations using multiomics and deep learning, facilitating optimal treatment design and expediting drug discovery in clinical settings. | ERC Advanced... | € 2.497.298 | 2023 | Details |
Artificial intelligence for synthetic functional genomics of bloodThis project aims to develop predictive models of gene regulatory elements and networks using deep learning and single-cell genetic screens to enhance gene regulation in hematopoiesis. | ERC Starting... | € 1.499.653 | 2022 | Details |
Engineering CAR-T cells to overcome glycosylation-driven tumour resistanceThe project aims to engineer CAR-T cells that express an enzyme to de-glycosylate tumor cells, enhancing their efficacy against solid cancers by overcoming immunosuppressive barriers. | ERC Starting... | € 1.500.000 | 2023 | Details |
Engineering B cells to fight cancer
This project aims to develop a novel cancer immunotherapy using engineered B cells to enhance anti-tumor responses through targeted gene integration and localized immune activation.
Polyclonal anti-tumor immunity by engineered human T cells
This project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes.
Learning and modeling the molecular response of single cells to drug perturbations
DeepCell aims to model cellular responses to drug perturbations using multiomics and deep learning, facilitating optimal treatment design and expediting drug discovery in clinical settings.
Artificial intelligence for synthetic functional genomics of blood
This project aims to develop predictive models of gene regulatory elements and networks using deep learning and single-cell genetic screens to enhance gene regulation in hematopoiesis.
Engineering CAR-T cells to overcome glycosylation-driven tumour resistance
The project aims to engineer CAR-T cells that express an enzyme to de-glycosylate tumor cells, enhancing their efficacy against solid cancers by overcoming immunosuppressive barriers.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Automated online monitoring & control to improve processes and decision making in cell and gene therapy manufacturingThe project aims to develop an automated, self-contained bioreactor with continuous monitoring of critical process parameters to enhance scalability and quality in cell and gene therapy manufacturing. | EIC Pathfinder | € 3.617.783 | 2022 | Details |
Bottom-up manufacturing of artificial anti-tumor T cellsThe project aims to develop Artificial T cells (ArTCells) that mimic T cell therapy's anti-tumor functions more safely and cost-effectively, using engineered Giant Unilamellar Vesicles for targeted cancer treatment. | EIC Pathfinder | € 3.391.796 | 2024 | Details |
CAR T cells Rewired to prevent EXhaustion in the tumour microenvironmentCAR T-REX aims to enhance CAR T cell efficacy against solid tumors by integrating auto-regulated genetic circuits to prevent exhaustion, using advanced gene editing and delivery technologies. | EIC Pathfinder | € 2.733.931 | 2023 | Details |
NOn-VIral gene modified STEM cell therapyThis project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application. | EIC Pathfinder | € 3.644.418 | 2022 | Details |
Exploiting ex vivo expansion and deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical applicationThis project aims to innovate hematopoietic stem cell identification and engineering through advanced culture techniques and multiomics profiling, enhancing gene therapy for blood disorders and cancer. | EIC Pathfinder | € 3.797.562 | 2022 | Details |
Automated online monitoring & control to improve processes and decision making in cell and gene therapy manufacturing
The project aims to develop an automated, self-contained bioreactor with continuous monitoring of critical process parameters to enhance scalability and quality in cell and gene therapy manufacturing.
Bottom-up manufacturing of artificial anti-tumor T cells
The project aims to develop Artificial T cells (ArTCells) that mimic T cell therapy's anti-tumor functions more safely and cost-effectively, using engineered Giant Unilamellar Vesicles for targeted cancer treatment.
CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment
CAR T-REX aims to enhance CAR T cell efficacy against solid tumors by integrating auto-regulated genetic circuits to prevent exhaustion, using advanced gene editing and delivery technologies.
NOn-VIral gene modified STEM cell therapy
This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.
Exploiting ex vivo expansion and deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical application
This project aims to innovate hematopoietic stem cell identification and engineering through advanced culture techniques and multiomics profiling, enhancing gene therapy for blood disorders and cancer.